|
Jul 22
|
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
|
|
Jul 22
|
Top Midday Decliners
|
|
Jul 22
|
Replimune Could Need 'Significant Restructuring' for RP1 Study Changes, Wedbush Says
|
|
Jul 22
|
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
|
|
Jul 22
|
BC-Most Active Stocks
|
|
Jul 22
|
FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink
|
|
Jul 22
|
Wall Street Set to Open Flat Tuesday; Powell Says US Banks Must Manage Key Risks
|
|
Jul 22
|
Replimune's Melanoma Therapy Denied FDA Approval, Shares Fall Sharply
|
|
Jul 22
|
Replimune drug rejected by FDA; Omega raises $647M biotech fund
|
|
Jul 22
|
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
|
|
Feb 12
|
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
|
|
Oct 2
|
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
|
|
Oct 1
|
Replimune to Present at Two Upcoming Investor Conferences
|
|
Sep 5
|
Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
|
|
Jun 3
|
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 16
|
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
|
|
Apr 7
|
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
|
|
Apr 4
|
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 26
|
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
|
|
Mar 11
|
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
|